Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jan 09, 2021 3:17pm
293 Views
Post# 32261709

RE:RE:The Ball is in THTX's Court

RE:RE:The Ball is in THTX's CourtTHTX is not the only biotech with promising prospects they are hundreds of small companies out there, again if we look at how they market themselves the ones who are proactively reaching out to investors are valued much more than the rest.
For instance as mentioned earlier some have a section re partnership in their website and often they already have teamed up with bigger pharmas, it is a very competitive market and the investor relation is as important as the rest of company's operations.
"If you can't beat them join them" is what THTX have to do.
Paul moved from a well established company to relatively unknown small biotech so he needs to realize he can't apply the same strategy.
Once they pass the hurdle being noticed by the market then they have a big audience following every move they make rather than some few hundred on this board and Stocktwits, the trick is to pass that hurdle...

<< Previous
Bullboard Posts
Next >>